Understanding how pancreatic cancer avoids the immune system
Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer
['FUNDING_CAREER'] · DANA-FARBER CANCER INST · NIH-10888266
This study is looking at how pancreatic cancer cells hide from the immune system and aims to find ways to help the body’s immune cells, especially T cells, better recognize and attack these cancer cells, which could lead to better treatments for patients.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10888266 on ClinicalTrials.gov |
What this research studies
This research investigates the ways pancreatic cancer cells evade detection and destruction by the immune system. By examining the molecular and cellular mechanisms involved, the study aims to identify specific immune responses that can be targeted for more effective treatments. Using advanced models and imaging techniques, researchers will analyze how certain immune cells, particularly T cells, behave in the presence of pancreatic tumors. The goal is to uncover strategies that could enhance the body's ability to fight this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic adenocarcinoma who may benefit from novel immunotherapy approaches.
Not a fit: Patients with other types of cancer or those without pancreatic cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve the immune system's ability to combat pancreatic cancer.
How similar studies have performed: Previous research has shown promise in understanding immune evasion in other cancers, suggesting that this approach could yield valuable insights for pancreatic cancer as well.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FREED-PASTOR, WILLIAM A — DANA-FARBER CANCER INST
- Study coordinator: FREED-PASTOR, WILLIAM A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.